| pubmed-article:6404867 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:6404867 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:6404867 | lifeskim:mentions | umls-concept:C0595989 | lld:lifeskim |
| pubmed-article:6404867 | lifeskim:mentions | umls-concept:C1521761 | lld:lifeskim |
| pubmed-article:6404867 | lifeskim:mentions | umls-concept:C0936012 | lld:lifeskim |
| pubmed-article:6404867 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:6404867 | pubmed:dateCreated | 1983-6-10 | lld:pubmed |
| pubmed-article:6404867 | pubmed:abstractText | Four hundred and ten patients with supraglottic laryngeal carcinoma treated with moderate dose radical radiotherapy with surgery for salvage (RRSS) were analyzed in detail to determine optimal dose-time-volume parameters to be used in the treatment of each stage of supraglottic carcinoma. In the RRSS group 41% are alive and well at 5 years, 38% died of their tumor and 21% of intercurrent disease. Presence or absence of nodal disease has a major impact on survival. Local control is approximately 70% in T1, T2N0 patients and approximately 50% in T3 and T4N0 patients. Seventeen percent of T1 and T2N0 patients failed in the initially negative neck. Ten major complications (2.4%) have been seen. Local control by irradiation was not influenced by dose or field size. Regional control in the initially negative neck was markedly increased with the use of larger irradiation field sizes. Field sizes of less than 7 X 7 cm resulted in an 18% neck failure rate as compared to 3% with larger field sizes (p = 0.00005). This particularly applied to early stage disease. As a result of the use of larger irradiation field sizes giving reduced neck failure rates, improvement in survival has been seen in early stage supraglottic patients. The results are compared with published results. There is no statistically significant dose response curve in any stage of supraglottic cancer over the dose range 1650-2300 ret. Optimal treatment factors for supraglottic cancer are discussed. | lld:pubmed |
| pubmed-article:6404867 | pubmed:language | eng | lld:pubmed |
| pubmed-article:6404867 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6404867 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:6404867 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6404867 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:6404867 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:6404867 | pubmed:issn | 0360-3016 | lld:pubmed |
| pubmed-article:6404867 | pubmed:author | pubmed-author:RiderW DWD | lld:pubmed |
| pubmed-article:6404867 | pubmed:author | pubmed-author:HarwoodA RAR | lld:pubmed |
| pubmed-article:6404867 | pubmed:author | pubmed-author:BealeF AFA | lld:pubmed |
| pubmed-article:6404867 | pubmed:author | pubmed-author:CummingsB JBJ | lld:pubmed |
| pubmed-article:6404867 | pubmed:author | pubmed-author:KeaneT JTJ | lld:pubmed |
| pubmed-article:6404867 | pubmed:author | pubmed-author:PayneD GDG | lld:pubmed |
| pubmed-article:6404867 | pubmed:author | pubmed-author:ElhakimTT | lld:pubmed |
| pubmed-article:6404867 | pubmed:author | pubmed-author:RawlinsonEE | lld:pubmed |
| pubmed-article:6404867 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:6404867 | pubmed:volume | 9 | lld:pubmed |
| pubmed-article:6404867 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:6404867 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:6404867 | pubmed:pagination | 311-9 | lld:pubmed |
| pubmed-article:6404867 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:6404867 | pubmed:meshHeading | pubmed-meshheading:6404867-... | lld:pubmed |
| pubmed-article:6404867 | pubmed:meshHeading | pubmed-meshheading:6404867-... | lld:pubmed |
| pubmed-article:6404867 | pubmed:meshHeading | pubmed-meshheading:6404867-... | lld:pubmed |
| pubmed-article:6404867 | pubmed:meshHeading | pubmed-meshheading:6404867-... | lld:pubmed |
| pubmed-article:6404867 | pubmed:meshHeading | pubmed-meshheading:6404867-... | lld:pubmed |
| pubmed-article:6404867 | pubmed:meshHeading | pubmed-meshheading:6404867-... | lld:pubmed |
| pubmed-article:6404867 | pubmed:meshHeading | pubmed-meshheading:6404867-... | lld:pubmed |
| pubmed-article:6404867 | pubmed:meshHeading | pubmed-meshheading:6404867-... | lld:pubmed |
| pubmed-article:6404867 | pubmed:meshHeading | pubmed-meshheading:6404867-... | lld:pubmed |
| pubmed-article:6404867 | pubmed:year | 1983 | lld:pubmed |
| pubmed-article:6404867 | pubmed:articleTitle | Supraglottic laryngeal carcinoma: an analysis of dose-time-volume factors in 410 patients. | lld:pubmed |
| pubmed-article:6404867 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:6404867 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:6404867 | lld:pubmed |
